Merck scores first US PD-1 approval

Share this article:
Merck scores first US PD-1 approval
Merck scores first US PD-1 approval

Merck is first to cross the US regulatory finish line for PD-1 inhibitors. The FDA approved the drug previously known as pembrolizumab, now known as Keytruda, for patients with unresectable or metastatic melanoma who have already taken Bristol-Myers Squibb's Yervoy (ipilimumab).

The FDA says melanoma accounts for around 5% of all new cancers diagnosed in the US. Merck's new drug is the sixth new melanoma treatment the regulator has approved since 2011, but this approval is a breakout for a drug class that has become a magnet for industry watchers. Multiple manufacturers are banking on immuno-oncology treatments, including AstraZeneca, Bristol-Myers and Roche.

The Street's Adam Feuerstein tweeted that a Merck spokesperson priced the new drug at $12,500 a month. A typical treatment will last 6.2 months.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.